A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Name: A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
Published: 2019
License: Public Domain

Kodiak Sciences Inc · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

wet macular degeneration, amd, wet amd, choroidal neovascularization secondary to age-related macular degeneration, ksi-301, aflibercept, vascular endothelial growth factor, vegf, anti-vegf, antibody biopolymer conjugate, macular degeneration, retinal degeneration

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 902605
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.